ghrelin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Aqueous buffers also used |
| Typical dry storage | -20 °C, desiccated, dark | Low moisture slows degradation |
| Identity method | Reversed-phase HPLC with mass detection | Retention time plus mass confirmation |
| Solution stability | Shorter than the dry solid | Cold storage, avoid freeze-thaw cycling |
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Glycolipid transfer proteins Lipocalins including retinol binding proteins and fatty acid-binding proteins Polyisoprenoid-binding protein, such as YceI protein domain Ganglioside GM2 activator proteins CRAL-TRIO domain (α-Tocopherol and phosphatidylinositol sec14p transfer proteins) Sterol carrier proteins Phosphatidylinositol transfer proteins and STAR domains Oxysterol-binding protein
Mostly containing a +5 species, which was immediately assigned to dubnium, it also had a +4 species; based on that result, the team decided that additional chemical separation was needed. In 2005, the experiment was repeated, with the final product being hydroxide rather than nitrate precipitate, which was processed further in both Livermore (based on reverse phase chromatography) and Dubna (based on anion exchange chromatography). The +5 species was effectively isolated; dubnium appeared three times in tantalum-only fractions and never in niobium-only fractions. It was noted that these experiments were insufficient to draw conclusions about the general chemical profile of dubnium. In 2009, at the JAEA tandem accelerator in Japan, dubnium was processed in nitric and hydrofluoric acid solution, at concentrations where niobium forms NbOF−4 and tantalum forms TaF−6. Dubnium's behavior was close to that of niobium but not tantalum; it was thus deduced that dubnium formed DbOF−4. From the available information, it was concluded that dubnium often behaved like niobium, sometimes like protactinium, but rarely like tantalum. In 2021, the volatile heavy group 5 oxychlorides MOCl3 (M = Nb, Ta, Db) were experimentally studied at the JAEA tandem accelerator. The trend in volatilities was found to be NbOCl3 > TaOCl3 ≥ DbOCl3, so that dubnium behaves in line with periodic trends.
== Bibliography == J. Samuel Walker (November 1, 2000). Permissible Dose: A History of Radiation Protection in the Twentieth Century. University of California Press. ISBN 978-0-520-92484-0. Limited preview in Google Books. K. N. Govinda Rajan (July 28, 2017). Radiation Safety in Radiation Oncology. CRC Press. ISBN 978-1-4987-6226-7. Limited preview in Google Books. Strahlengefahrdung und Strahlenschutz / Radiation Exposure and Radiation Protection. Springer-Publisher. March 13, 2013. ISBN 978-3-642-82229-2. Limited preview in Google Books J. Samuel Walker (April 2001). Short History of Nuclear Regulation, 1946–1999. DIANE Publishing. ISBN 978-0-7567-0929-7.Limited preview in Google Books. Ashley W. Oughterson, Shields Warren: Medical Effects of the Atomic Bomb in Japan. Volume VIII.8 aus der National Nuclear Energy Series zum Manhattan Project, McGraw-Hill Book Company, 1956. Carl Voegtlin, Harold C. Hodge: Pharmacology and Toxicology of Uranium Compounds. Volume VI.1, Part I and Part II (with a Section on the Pharmacology and Toxicology of Fluorine and Hydrogen Fluoride) from the National Nuclear Energy Series to the Manhattan Project, McGraw-Hill Book Company, 1949. Henry DeWolf Smyth (written on the request of Maj. Gen. L. R. Groves): Atomic Energy for Military Purposes. The official report on the development of the atomic bomb under the auspices of the United States Government, 1940–1945. Princeton University Press, 1946. James E. Grindler (Argonne National Laboratory): The Radiochemistry of Uranium.
Sources: en.wikipedia.org
Osteolathyrism, sometimes referred to as odoratism, is a form of the disease Lathyrism. The disease results from the ingestion of Lathyrus odoratus seeds (sweet peas). The toxin found in the sweet peas is (beta-aminopropionitrile), which affects the linking of collagen, a protein of connective tissues. The condition results in damage to bone and mesenchymal connective tissues. Osteolathyrism occurs in people in combination with neurolathyrism and angiolathyrism in areas where famine demands reliance on a crop with known detrimental effects. It occurs in cattle and horses with diets overreliant upon the grass pea. Prominent symptoms include skeletal deformities and bone pain.
Berkelium is a soft, silvery-white, radioactive metal. The berkelium-249 isotope emits low-energy beta particles and thus is relatively safe to handle. It decays with a half-life of 330 days to californium-249, which is a strong emitter of ionizing alpha particles. This gradual transmutation is an important consideration when studying the properties of elemental berkelium and its chemical compounds, since the formation of californium brings not only chemical contamination, but also free-radical effects and self-heating from the emitted alpha particles.
Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses. Interferon beta has not been shown to slow the advance of disability. Interferons are not a cure for MS (there is no known cure); the claim is that interferons may slow the progress of the disease if started early and continued for the duration of the disease.
Some publications write the nucleotides in a different order (e.g., some authors choose to group two purines together and the two pyrimidines together; see also models of DNA evolution). These differences in notation make it important to be clear regarding the order of the states when writing the
Sources: en.wikipedia.org
Typical guidance is -20 °C in a sealed container with desiccant and protection from light. The powder tolerates handling better than a solution, but repeated warming and cooling is still avoided.
Chromatography separates components by retention behavior, while mass spectrometry reports molecular mass and fragment patterns. Together they confirm identity and reveal modifications that a single retention time could miss.
Immunoassays are useful for estimating concentrations in biological samples but depend on antibody specificity. Related secretagogues or fragments may bind the same antibody, so cross-reactivity limits their use for definitive identity confirmation.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.